Catalyst
Slingshot members are tracking this event:
Mallinckrodt (MNK) to complete Phase 2A study of Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
- Source Link:
- https://clinicaltrials.gov/ct2/show/NCT01601236
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Occurred Source:
https://clinicaltrials.gov/archive/NCT01601236/2016_11_28/changes
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Diabetic Nephropathy, Repository Corticotropin Injection, Acthar, Proteinuria, Phase 2a Study
